Table 3 Summary of second primary malignancies in the safety population.

From: Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study

 

D-Rd (n = 283)

Rd (n = 281)

Total, n (%)

24 (8.5)

25 (8.9)

   Cutaneous/noninvasive

12 (4.2)

10 (3.6)

   Noncutaneous/invasive

8 (2.8)

11 (3.9)

   Hematologic

5 (1.8)

3 (1.1)

  1. D-Rd daratumumab/lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone.
Back to article page